Elsevier

Journal of Hepatology

Volume 66, Issue 2, February 2017, Pages 267-269
Journal of Hepatology

Editorial
The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection

https://doi.org/10.1016/j.jhep.2016.10.027Get rights and content

Section snippets

Financial support

Dr. Sulkowski received support through a NIH mid-career mentor award, K24 DA034621 and R01DA16065. Dr. Falade-Nwulia was supported by a NIH Mentored Patient-Oriented Research Career Development Award K23 DA041294.

Conflict of interest

Dr. Falade-Nwulia has nothing to disclose. Dr. Sulkowski reports research grants and personal fees from AbbVie, personal fees from Cocrystal, research grants and personal fees from Gilead, research grants and personal fees from Janssen, research grants and personal fees from Merck, and personal fees from Trek.

Authors’ contributions

Dr. Falade-Nwulia wrote the first draft of the manuscript; Dr. Sulkowski provided critical revisions to the work and created the figure. Both authors approved the final submission.

References (14)

  • H. Midgard et al.

    Hepatitis C reinfection after sustained virological response

    J Hepatol

    (2016)
  • P. Ingiliz et al.

    HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe

    J Hepatol

    (2017)
  • World Health Organization: Draft global health sector strategy on viral hepatitis, 2016–2021 – The first of it’s kind,...
  • N.K. Martin et al.

    Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

    Hepatology

    (2013)
  • N.K. Martin et al.

    Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights

    Clin Infect Dis

    (2016)
  • F.A. Lambers et al.

    Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM

    Aids

    (2011)
  • T.C. Martin et al.

    Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM

    Aids

    (2013)
There are more references available in the full text version of this article.

Cited by (12)

  • Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis

    2021, Gastroenterologia y Hepatologia
    Citation Excerpt :

    Nevertheless, the really special conditions of the population studied (HIV+, MSM, high risk STD) is a remarkable strength, in order to assess the efficacy of early health interventions in those patients. As other authors have described,19,21 we face a group of patients with risky sexual practices, often related to drug use, who have a high risk of contracting sexually transmitted diseases. In these patients, in addition to providing treatment for HCV and other STDs, we must keep them linked to the medical care system to preserve the effect of the cure and detect possible reinfections, implement behavioral interventions aimed at reducing damage and offer help in the addiction management.

  • An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages

    2020, Journal of Hepatology
    Citation Excerpt :

    Therefore, to achieve the goal of elimination of hepatitis C infection in Egypt, the strategy of elimination needs to be increasingly directed towards case-finding through mass screening in rural communities to identify and treat those not yet aware of their diagnosis.10 A further issue has been the continued high rate of new infections, estimated at 2–6 cases per 1,000 (equivalent to at least 170,000 new cases) per year9 due to unsafe injection and health care practices,10 highlighting the need for concomitant effective awareness raising and education campaigns to prevent new infections.11 We developed a community-based outreach model (educate, test and treat) for the prevention, diagnosis and treatment of hepatitis C infection across villages in rural Egypt, but applicable to other high burden countries.

View all citing articles on Scopus
View full text